Bayer’s asundexian, a Factor XIa inhibitor, reduced the risk of secondary stroke by 26% without increasing bleeding risk in a Phase 3 clinical trial. The once-daily pill is at the front of an emerging class of medicines that includes drug candidates from Regeneron Pharmaceuticals and partners Bristol Myers Squibb and Johnson & Johnson.
The post Bayer Reveals Data That Could Make Stroke Prevention Drug Its Next Blockbuster Product appeared first on MedCity News.
